Tags

Type your tag names separated by a space and hit enter

International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
Am J Obstet Gynecol 2007; 197(3 Suppl):S42-55AJ

Abstract

The World Health Organization recommends that countries adopt more effective antiretroviral regimens to increase the effectiveness of the prevention of mother-to-child human immunodeficiency virus (HIV) transmission programs. The 2006 guidelines recommend a tiered approach for the delivery of antiretroviral to pregnant women who are infected with HIV and include triple-drug antiretroviral treatment for those women who are eligible. Those women who are not eligible for antiretroviral treatment should receive a combination prophylaxis antiretroviral regimen, preferably zidovudine from 28 weeks of gestation; zidovudine, lamivudine, and a single dose of nevirapine during delivery; and zidovudine and lamivudine for 7 days after delivery to reduce the development of nevirapine resistance. Newborn infants should receive a single dose of nevirapine and 1-4 weeks of zidovudine, depending on the duration of the regimen received by the mother. Although steps are being taken to provide more effective regimens, the use of single-dose nevirapine alone should still be used in situations in which more effective regimens are not yet feasible or available. HIV transmission through breastfeeding remains a problem, and several interventions are under evaluation that include maternal and/or infant antiretroviral prophylaxis during breastfeeding.

Authors+Show Affiliations

Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, TB Prevention, Atlanta, GA, USA. hcd1@cdc.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Practice Guideline
Review

Language

eng

PubMed ID

17825650

Citation

Dao, Halima, et al. "International Recommendations On Antiretroviral Drugs for Treatment of HIV-infected Women and Prevention of Mother-to-child HIV Transmission in Resource-limited Settings: 2006 Update." American Journal of Obstetrics and Gynecology, vol. 197, no. 3 Suppl, 2007, pp. S42-55.
Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol. 2007;197(3 Suppl):S42-55.
Dao, H., Mofenson, L. M., Ekpini, R., Gilks, C. F., Barnhart, M., Bolu, O., & Shaffer, N. (2007). International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. American Journal of Obstetrics and Gynecology, 197(3 Suppl), pp. S42-55.
Dao H, et al. International Recommendations On Antiretroviral Drugs for Treatment of HIV-infected Women and Prevention of Mother-to-child HIV Transmission in Resource-limited Settings: 2006 Update. Am J Obstet Gynecol. 2007;197(3 Suppl):S42-55. PubMed PMID: 17825650.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. AU - Dao,Halima, AU - Mofenson,Lynne M, AU - Ekpini,Rene, AU - Gilks,Charles F, AU - Barnhart,Matthew, AU - Bolu,Omotayo, AU - Shaffer,Nathan, PY - 2006/12/14/received PY - 2007/02/22/revised PY - 2007/03/01/accepted PY - 2007/9/14/pubmed PY - 2007/9/26/medline PY - 2007/9/14/entrez SP - S42 EP - 55 JF - American journal of obstetrics and gynecology JO - Am. J. Obstet. Gynecol. VL - 197 IS - 3 Suppl N2 - The World Health Organization recommends that countries adopt more effective antiretroviral regimens to increase the effectiveness of the prevention of mother-to-child human immunodeficiency virus (HIV) transmission programs. The 2006 guidelines recommend a tiered approach for the delivery of antiretroviral to pregnant women who are infected with HIV and include triple-drug antiretroviral treatment for those women who are eligible. Those women who are not eligible for antiretroviral treatment should receive a combination prophylaxis antiretroviral regimen, preferably zidovudine from 28 weeks of gestation; zidovudine, lamivudine, and a single dose of nevirapine during delivery; and zidovudine and lamivudine for 7 days after delivery to reduce the development of nevirapine resistance. Newborn infants should receive a single dose of nevirapine and 1-4 weeks of zidovudine, depending on the duration of the regimen received by the mother. Although steps are being taken to provide more effective regimens, the use of single-dose nevirapine alone should still be used in situations in which more effective regimens are not yet feasible or available. HIV transmission through breastfeeding remains a problem, and several interventions are under evaluation that include maternal and/or infant antiretroviral prophylaxis during breastfeeding. SN - 1097-6868 UR - https://www.unboundmedicine.com/medline/citation/17825650/International_recommendations_on_antiretroviral_drugs_for_treatment_of_HIV_infected_women_and_prevention_of_mother_to_child_HIV_transmission_in_resource_limited_settings:_2006_update_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9378(07)00291-8 DB - PRIME DP - Unbound Medicine ER -